{"protocolSection":{"identificationModule":{"nctId":"NCT02422940","orgStudyIdInfo":{"id":"DALF-PS-1029"},"organization":{"fullName":"Acorda Therapeutics","class":"INDUSTRY"},"briefTitle":"Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.","officialTitle":"An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets. for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits .","acronym":"MILESTONE℠"},"statusModule":{"statusVerifiedDate":"2018-08","overallStatus":"TERMINATED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-04"},"primaryCompletionDateStruct":{"date":"2017-01","type":"ACTUAL"},"completionDateStruct":{"date":"2017-01","type":"ACTUAL"},"studyFirstSubmitDate":"2015-04-14","studyFirstSubmitQcDate":"2015-04-17","studyFirstPostDateStruct":{"date":"2015-04-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-02-06","resultsFirstSubmitQcDate":"2018-08-07","resultsFirstPostDateStruct":{"date":"2018-08-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-01-17","lastUpdatePostDateStruct":{"date":"2019-01-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Acorda Therapeutics","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.","detailedDescription":"This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER twice daily tablets when administered for at least 12 months to subjects with chronic post-ischemic stroke walking deficits who have completed the controlled, double-blind Study DALF-PS-1016."},"conditionsModule":{"conditions":["Post-ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":294,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"dalfampridine-ER 7.5 mg","type":"ACTIVE_COMPARATOR","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.","interventionNames":["Drug: dalfampridine-ER 7.5 mg"]},{"label":"dalfampridine-ER 10 mg","type":"ACTIVE_COMPARATOR","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.","interventionNames":["Drug: dalfampridine-ER 10 mg"]}],"interventions":[{"type":"DRUG","name":"dalfampridine-ER 7.5 mg","armGroupLabels":["dalfampridine-ER 7.5 mg"]},{"type":"DRUG","name":"dalfampridine-ER 10 mg","armGroupLabels":["dalfampridine-ER 10 mg"],"otherNames":["Ampyra™"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Primary Objective Was to Evaluate Serious and Non-serious Adverse Events for Study Participants as a Measure of Safety and Tolerability of Dalfampridine ER (Extended Release) for at Least 12-months.","description":"This extension study was designed to evaluate long-term safety, tolerability, and efficacy of dalfampridine-ER (extended release) in adult subjects with chronic post-ischemic stroke walking deficits. Subjects who had completed the placebo-controlled DALF-PS-1016 core study were eligible to enroll regardless of whether they had received active drug or placebo in the core study.","timeFrame":"up to 12 months"}],"secondaryOutcomes":[{"measure":"Change From Baseline on the Two-Minute Walk Test (2MinWT)","description":"2 Minute Walk Test (2MinWT) and Change from Baseline by Visit","timeFrame":"Day 1, up to 12 months"},{"measure":"Change From Baseline on the 10 Meter Walk Test (10MWT)","description":"10 Meter Walk Test (10MWT) and Change from Baseline by Visit","timeFrame":"Day 1, up to 12 months"},{"measure":"Change From Baseline on the Timed up and Go (TUG) Test","description":"The TUG measures mobility and balance and can predict the risk of falls. This test, which was initially called the Get-up and Go test, is considered a measure of dynamic balance. The subject is asked to stand up from a chair, walk 10 feet at a comfortable pace, turn around and be seated. The Timed Up and Go (TUG) is measured in seconds. There will be one practice test and then the timed test. Only the timed test will be analyzed at each visit time point. Reciprocal transformation may be performed if the time values are markedly skewed.","timeFrame":"Day 1, up to 12 months"},{"measure":"Change From Baseline on the Walking Impact Scale (Walk-12)","description":"The Walk-12 is a 12-question questionnaire that asks subjects to rate limitations of their mobility during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). For each visit, the Walk-12 score will be calculated by summing the 12 components and transforming into a scale with a range of 0 to 100. A higher score indicates a greater degree of limitation in walking. A negative change indicates an improvement in walking. 0 = no limitation in mobility to 100 extreme limitation in mobility. Walk-12 Score = 100 \\* \\[(Mean of the 12 items) - 1\\]/(5-1)","timeFrame":"Day 1, up to 12 months"},{"measure":"Change From Baseline on the Stroke Impact Scale (SIS)","description":"The SIS consists of 59 items grouped in 8 domains: strength, hand function, activities of daily living (ADL) / instrumental activities of daily living (IADL), mobility, communication, emotion, memory and thinking, and participation/role function. The subject is asked to rate the level of difficulty in performing each item in the preceding week. Each item is scored on a 5-point scale ranging from 1 (inability to complete the item) to 5 (no difficulty experienced at all). For each domain, the SIS score will be calculated by summing all the items within the domain and transforming into a scale with a range of 0 to 100 as follows: SIS Score = 100 \\* \\[(Actual raw score - Lowest possible raw score)/ (Highest possible raw score-Lowest possible raw score)\\].","timeFrame":"Day 1, up to 12 months"},{"measure":"Subject Global Impression (SGI)","description":"The Subject Global Impression (SGI) is single item measure of treatment response that asks the subject to rate the effects of the investigational drug on his or her overall walking ability using a 7 point scale ranging from 1 = \"Terrible\" to 7 = \"Delighted.\"","timeFrame":"Visit 8 (Month 12)"},{"measure":"Change From Baseline on the 12-item Health Survey (SF-12)","description":"The SF-12 v2 (4-week recall) is a general health-related quality-of-life profile measure consisting of 12 items. The SF-12 Physical Component Summary (PCS) and the Mental Component Summary (MCS) scores will be derived and normed to a general United States population for score algorithm. The normalized PCS and MCS scores will be calculated at baseline, Month 12, and subsequent visits.\n\nSF-12 is a Physical and Mental Health Composite Scores (PCS \\& MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.","timeFrame":"Day 1, up to 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Completion of the DALF-PS-1016 study\n* Providing informed consent to continue into the DALF-PS-1029 long-term extension study\n* Sufficient ambulatory ability to independently complete the Two Minute Walk Test (2MinWT) and 10 Meter Walk Test (10MWT) at the time of enrollment into the extension study\n\nKey Exclusion Criteria:\n\n* Seizures, new onset strokes (or other significant neurological event precluding long-term continuation) occurring during the antecedent DALF-PS-1016 study\n* Calculated creatinine clearance of ≤ 50 mL/minute at the time of enrollment into the long-term extension study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Holly Roberts, MD","affiliation":"Acorda Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Acorda Site #117","city":"Gilbert","state":"Arizona","zip":"85234","country":"United States","geoPoint":{"lat":33.35283,"lon":-111.78903}},{"facility":"Acorda Site #109","city":"Berkeley","state":"California","zip":"94705","country":"United States","geoPoint":{"lat":37.87159,"lon":-122.27275}},{"facility":"Acorda Site #170","city":"Carlsbad","state":"California","zip":"92011","country":"United States","geoPoint":{"lat":33.15809,"lon":-117.35059}},{"facility":"Acorda Site #138","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Acorda Site #105","city":"Newport Beach","state":"California","zip":"92663","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Acorda Site #142","city":"Pasadena","state":"California","zip":"91105","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Acorda Site #153","city":"Sacramento","state":"California","zip":"95823","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Acorda Site #151","city":"San Diego","state":"California","zip":"921018466","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Acorda Site #163","city":"San Diego","state":"California","zip":"92123","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Acorda Site #124","city":"Colorado Springs","state":"Colorado","zip":"80907","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Acorda Site #110","city":"Danbury","state":"Connecticut","zip":"06810","country":"United States","geoPoint":{"lat":41.39482,"lon":-73.45401}},{"facility":"Acorda Site #149","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"Acorda Site #130","city":"Stamford","state":"Connecticut","zip":"06905","country":"United States","geoPoint":{"lat":41.05343,"lon":-73.53873}},{"facility":"Acorda Site #115","city":"Atlantis","state":"Florida","zip":"33462","country":"United States","geoPoint":{"lat":26.5909,"lon":-80.10088}},{"facility":"Acorda Site #119","city":"Deerfield Beach","state":"Florida","zip":"33441","country":"United States","geoPoint":{"lat":26.31841,"lon":-80.09977}},{"facility":"Acorda Site #147","city":"Gainesville","state":"Florida","zip":"326100236","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Acorda Site #128","city":"Hialeah","state":"Florida","zip":"33012","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Acorda Site #184","city":"Jacksonville","state":"Florida","zip":"32277","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Acorda Site #103","city":"Miami","state":"Florida","zip":"33142","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Acorda Site #133","city":"Miami","state":"Florida","zip":"33175","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Acorda Site #161","city":"Naples","state":"Florida","zip":"34102","country":"United States","geoPoint":{"lat":26.14234,"lon":-81.79596}},{"facility":"Acorda Site #106","city":"Tampa","state":"Florida","zip":"33606","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"Acorda Site #181","city":"Honolulu","state":"Hawaii","zip":"96817","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Acorda Site #171","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Acorda Site #148","city":"Avon","state":"Indiana","zip":"46123","country":"United States","geoPoint":{"lat":39.76282,"lon":-86.39972}},{"facility":"Acorda Site #188","city":"Fort Wayne","state":"Indiana","zip":"46804","country":"United States","geoPoint":{"lat":41.1306,"lon":-85.12886}},{"facility":"Acorda Site #156","city":"Franklin","state":"Indiana","zip":"46131","country":"United States","geoPoint":{"lat":39.48061,"lon":-86.05499}},{"facility":"Acorda Site #146","city":"Lexington","state":"Kentucky","zip":"40513","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"Acorda Site #150","city":"New Orleans","state":"Louisiana","zip":"70121","country":"United States","geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Acorda Site #175","city":"Fulton","state":"Maryland","zip":"20759","country":"United States","geoPoint":{"lat":39.15094,"lon":-76.92303}},{"facility":"Acorda Site #136","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Acorda Site #121","city":"Boston","state":"Massachusetts","zip":"02118","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Acorda Site #123","city":"East Lansing","state":"Michigan","zip":"48824","country":"United States","geoPoint":{"lat":42.73698,"lon":-84.48387}},{"facility":"Acorda Site #164","city":"Farmington Hills","state":"Michigan","zip":"48334","country":"United States","geoPoint":{"lat":42.48531,"lon":-83.37716}},{"facility":"Acorda Site #159","city":"Grand Rapids","state":"Michigan","zip":"49503","country":"United States","geoPoint":{"lat":42.96336,"lon":-85.66809}},{"facility":"Acorda Site #101","city":"Kansas City","state":"Missouri","zip":"64132","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Acorda Site #111","city":"Great Falls","state":"Montana","zip":"59405","country":"United States","geoPoint":{"lat":47.50024,"lon":-111.30081}},{"facility":"Acorda Site #140","city":"Reno","state":"Nevada","zip":"89502","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Acorda Site #131","city":"New Brunswick","state":"New Jersey","zip":"08901","country":"United States","geoPoint":{"lat":40.48622,"lon":-74.45182}},{"facility":"Acorda Site #177","city":"Stratford","state":"New Jersey","zip":"08084","country":"United States","geoPoint":{"lat":39.82678,"lon":-75.01545}},{"facility":"Acorda Site #172","city":"New York","state":"New York","zip":"10029","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Acorda Site #179","city":"Patchogue","state":"New York","zip":"11772","country":"United States","geoPoint":{"lat":40.76565,"lon":-73.01511}},{"facility":"Acorda Site #114","city":"White Plains","state":"New York","zip":"10605","country":"United States","geoPoint":{"lat":41.03399,"lon":-73.76291}},{"facility":"Acorda Site #166","city":"Chapel Hill","state":"North Carolina","zip":"27599","country":"United States","geoPoint":{"lat":35.9132,"lon":-79.05584}},{"facility":"Acorda Site #167","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Acorda Site #162","city":"Mooresville","state":"North Carolina","zip":"28117","country":"United States","geoPoint":{"lat":35.58486,"lon":-80.81007}},{"facility":"Acorda Site #154","city":"Raleigh","state":"North Carolina","zip":"276076010","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Acorda Site #132","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Acorda Site #137","city":"Columbus","state":"Ohio","zip":"43210","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Acorda Site #116","city":"Dayton","state":"Ohio","zip":"45417","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Acorda Site #152","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Acorda Site #168","city":"Portland","state":"Oregon","zip":"97225","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Acorda Site #126","city":"Portland","state":"Oregon","zip":"97239","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Acorda Site #122","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Acorda Site #144","city":"Providence","state":"Rhode Island","zip":"02903","country":"United States","geoPoint":{"lat":41.82399,"lon":-71.41283}},{"facility":"Acorda Site #157","city":"Memphis","state":"Tennessee","zip":"38163","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Acorda Site #113","city":"Dallas","state":"Texas","zip":"75214","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Acorda Site #165","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Acorda Site #108","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Acorda Site #182","city":"Falls Church","state":"Virginia","zip":"22043","country":"United States","geoPoint":{"lat":38.88233,"lon":-77.17109}},{"facility":"Acorda Site #176","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}},{"facility":"Acorda Site #107","city":"Spokane","state":"Washington","zip":"992021330","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Acorda Site #203","city":"Fredericton","state":"New Brunswick","zip":"E3B0C7","country":"Canada","geoPoint":{"lat":45.94541,"lon":-66.66558}},{"facility":"Acorda Site #202","city":"Halifax","state":"Nova Scotia","zip":"B3H4K4","country":"Canada","geoPoint":{"lat":44.64533,"lon":-63.57239}},{"facility":"Acorda Site #201","city":"Greenfield Park","state":"Quebec","zip":"J4V2H1","country":"Canada","geoPoint":{"lat":45.48649,"lon":-73.46223}},{"facility":"Acorda Site #204","city":"Montréal","state":"Quebec","zip":"H3G1A4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"FG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"142"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"21"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"121"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"BG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"294"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"294"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.1","spread":"10.87"},{"groupId":"BG001","value":"64.6","spread":"10.32"},{"groupId":"BG002","value":"63.3","spread":"10.67"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"104"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"190"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Canada","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"133"},{"groupId":"BG002","value":"277"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Objective Was to Evaluate Serious and Non-serious Adverse Events for Study Participants as a Measure of Safety and Tolerability of Dalfampridine ER (Extended Release) for at Least 12-months.","description":"This extension study was designed to evaluate long-term safety, tolerability, and efficacy of dalfampridine-ER (extended release) in adult subjects with chronic post-ischemic stroke walking deficits. Subjects who had completed the placebo-controlled DALF-PS-1016 core study were eligible to enroll regardless of whether they had received active drug or placebo in the core study.","populationDescription":"The Safety Population of 293 subjects included all subjects who received at least one dose of study treatment.\n\n\\*One subject was randomized but discontinued the study prior to receiving double-blind study treatment","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"up to 12 months","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"142"}]}],"classes":[{"title":"Subjects with at Least One TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"99"}]}]},{"title":"Subjects with at Least One Serious TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"}]}]},{"title":"Subjects by Maximum Severity (Mild)","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"45"}]}]},{"title":"Subjects by Maximum Severity (Moderate)","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"43"}]}]},{"title":"Subjects by Maximum Severity (Severe)","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"}]}]},{"title":"Subjects with at least One TEAEA leading to Discon","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"}]}]},{"title":"Subjects who Died Due to a TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the Two-Minute Walk Test (2MinWT)","description":"2 Minute Walk Test (2MinWT) and Change from Baseline by Visit","populationDescription":"The study was conducted in patients with chronic walking deficits from an ischemic stroke.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Feet","timeFrame":"Day 1, up to 12 months","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"309.59","spread":"132.956"},{"groupId":"OG001","value":"297.41","spread":"143.722"}]}]},{"title":"Visit 2 (Day 15) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"319.24","spread":"135.072"},{"groupId":"OG001","value":"312.08","spread":"146.818"}]}]},{"title":"Visit 2 (Day 15) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.72","spread":"34.898"},{"groupId":"OG001","value":"14.27","spread":"34.824"}]}]},{"title":"Visit 3 (Month 1) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"128"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"322.95","spread":"136.511"},{"groupId":"OG001","value":"317.96","spread":"146.419"}]}]},{"title":"Visit 3 (Month 1) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"128"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.81","spread":"40.457"},{"groupId":"OG001","value":"14.48","spread":"39.961"}]}]},{"title":"Visit 4 (Month 2) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"328.01","spread":"139.437"},{"groupId":"OG001","value":"318.98","spread":"147.429"}]}]},{"title":"Visit 4 (Month 2) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"34.512"},{"groupId":"OG001","value":"17.48","spread":"37.385"}]}]},{"title":"Visit 5 (Month 3) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"323.29","spread":"136.815"},{"groupId":"OG001","value":"331.77","spread":"140.872"}]}]},{"title":"Visit 5 (Month 3) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.44","spread":"41.635"},{"groupId":"OG001","value":"16.99","spread":"41.207"}]}]},{"title":"Visit 6 (Month 6) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"335.28","spread":"128.117"},{"groupId":"OG001","value":"321.28","spread":"133.484"}]}]},{"title":"Visit 6 (Month 6) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"72"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.38","spread":"38.767"},{"groupId":"OG001","value":"72","spread":"10.00"}]}]},{"title":"Visit 7 (Month 9) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"312.98","spread":"136.536"},{"groupId":"OG001","value":"342.24","spread":"129.673"}]}]},{"title":"Visit 7 (Month 9) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"41"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.88","spread":"45.327"},{"groupId":"OG001","value":"19.25","spread":"33.597"}]}]},{"title":"Visit 8 (Month 12) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"330.07","spread":"144.749"},{"groupId":"OG001","value":"360.90","spread":"107.895"}]}]},{"title":"Visit 8 (Month 12) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.65","spread":"50.899"},{"groupId":"OG001","value":"19.98","spread":"34.067"}]}]},{"title":"Final Visit - Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"320.34","spread":"136.425"},{"groupId":"OG001","value":"318.48","spread":"126.718"}]}]},{"title":"Final Visit - Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.23","spread":"50.991"},{"groupId":"OG001","value":"9.88","spread":"51.867"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the 10 Meter Walk Test (10MWT)","description":"10 Meter Walk Test (10MWT) and Change from Baseline by Visit","populationDescription":"The study was conducted in patients with chronic walking deficits from an ischemic stroke.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Meter /second","timeFrame":"Day 1, up to 12 months","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":"0.454"},{"groupId":"OG001","value":"0.89","spread":"0.472"}]}]},{"title":"Visit 2 (Day 15) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"0.498"},{"groupId":"OG001","value":"0.94","spread":"0.494"}]}]},{"title":"Visit 2 (Day 15) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"135"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.118"},{"groupId":"OG001","value":"0.05","spread":"0.124"}]}]},{"title":"Visit 3 (Month 1) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.470"},{"groupId":"OG001","value":"0.98","spread":"0.494"}]}]},{"title":"Visit 3 (Month 1) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"127"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.124"},{"groupId":"OG001","value":"0.06","spread":"0.122"}]}]},{"title":"Visit 4 (Month 2) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.502"},{"groupId":"OG001","value":"0.98","spread":"0.503"}]}]},{"title":"Visit 4 (Month 2) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"125"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.136"},{"groupId":"OG001","value":"0.08","spread":"0.134"}]}]},{"title":"Visit 5 (Month 3) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"0.489"},{"groupId":"OG001","value":"1.00","spread":"0.488"}]}]},{"title":"Visit 5 (Month 3) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"108"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.146"},{"groupId":"OG001","value":"0.08","spread":"0.167"}]}]},{"title":"Visit 6 (Month 6) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.497"},{"groupId":"OG001","value":"0.99","spread":"0.456"}]}]},{"title":"Visit 6 (Month 6) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.145"},{"groupId":"OG001","value":"0.07","spread":"0.124"}]}]},{"title":"Visit 7 (Month 9) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.582"},{"groupId":"OG001","value":"1.06","spread":"0.400"}]}]},{"title":"Visit 7 (Month 9) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"0.205"},{"groupId":"OG001","value":"0.08","spread":"0.145"}]}]},{"title":"Visit 8 (Month 12) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"0.563"},{"groupId":"OG001","value":"1.08","spread":"0.414"}]}]},{"title":"Visit 8 (Month 12) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.198"},{"groupId":"OG001","value":"0.06","spread":"0.238"}]}]},{"title":"Final Visit - Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"0.534"},{"groupId":"OG001","value":"0.91","spread":"0.425"}]}]},{"title":"Final Visit - Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.199"},{"groupId":"OG001","value":"-0.03","spread":"0.263"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the Timed up and Go (TUG) Test","description":"The TUG measures mobility and balance and can predict the risk of falls. This test, which was initially called the Get-up and Go test, is considered a measure of dynamic balance. The subject is asked to stand up from a chair, walk 10 feet at a comfortable pace, turn around and be seated. The Timed Up and Go (TUG) is measured in seconds. There will be one practice test and then the timed test. Only the timed test will be analyzed at each visit time point. Reciprocal transformation may be performed if the time values are markedly skewed.","populationDescription":"The study was conducted in patients with chronic walking deficits from an ischemic stroke.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Seconds","timeFrame":"Day 1, up to 12 months","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"17.92","spread":"19.899"},{"groupId":"OG001","value":"20.16","spread":"18.587"}]}]},{"title":"Visit 2 (Day 15) Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"18.59","spread":"30.461"},{"groupId":"OG001","value":"19.82","spread":"20.019"}]}]},{"title":"Visit 2 (Day 15) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"12.640"},{"groupId":"OG001","value":"-0.40","spread":"4.844"}]}]},{"title":"Visit 3 (Month 1) Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"17.28","spread":"21.165"},{"groupId":"OG001","value":"18.76","spread":"19.267"}]}]},{"title":"Visit 3 (Month 1) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":"3.215"},{"groupId":"OG001","value":"-0.61","spread":"7.329"}]}]},{"title":"Visit 4 (Month 2) Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"17.57","spread":"22.351"},{"groupId":"OG001","value":"18.49","spread":"16.563"}]}]},{"title":"Visit 4 (Month 2) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"3.644"},{"groupId":"OG001","value":"-1.32","spread":"4.816"}]}]},{"title":"Visit 5 (Month 3) Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"18.10","spread":"26.829"},{"groupId":"OG001","value":"17.39","spread":"16.509"}]}]},{"title":"Visit 5 (Month 3) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"7.321"},{"groupId":"OG001","value":"-1.60","spread":"4.323"}]}]},{"title":"Visit 6 (Month 6) Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"17.75","spread":"31.394"},{"groupId":"OG001","value":"17.07","spread":"15.532"}]}]},{"title":"Visit 6 (Month 6) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"9.273"},{"groupId":"OG001","value":"-1.36","spread":"4.740"}]}]},{"title":"Visit 7 (Month 9) Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"22.93","spread":"39.918"},{"groupId":"OG001","value":"15.85","spread":"14.085"}]}]},{"title":"Visit 7 (Month 9) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"11.085"},{"groupId":"OG001","value":"-1.08","spread":"3.452"}]}]},{"title":"Visit 8 (Month 12) Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"16.80","spread":"13.724"},{"groupId":"OG001","value":"15.17","spread":"15.635"}]}]},{"title":"Visit 8 (Month 12) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"4.536"},{"groupId":"OG001","value":"-0.50","spread":"2.606"}]}]},{"title":"Final Visit - Actual Value","categories":[{"measurements":[{"groupId":"OG000","value":"17.38","spread":"15.967"},{"groupId":"OG001","value":"19.21","spread":"20.596"}]}]},{"title":"Final Visit - Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"6.416"},{"groupId":"OG001","value":"1.25","spread":"6.914"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the Walking Impact Scale (Walk-12)","description":"The Walk-12 is a 12-question questionnaire that asks subjects to rate limitations of their mobility during the preceding two weeks on a 5-point scale (from 1= not at all to 5=extremely). For each visit, the Walk-12 score will be calculated by summing the 12 components and transforming into a scale with a range of 0 to 100. A higher score indicates a greater degree of limitation in walking. A negative change indicates an improvement in walking. 0 = no limitation in mobility to 100 extreme limitation in mobility. Walk-12 Score = 100 \\* \\[(Mean of the 12 items) - 1\\]/(5-1)","populationDescription":"The study was conducted in patients with chronic walking deficits from an ischemic stroke.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Day 1, up to 12 months","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.37","spread":"26.933"},{"groupId":"OG001","value":"49.78","spread":"26.583"}]}]},{"title":"Visit 2 (Day 15) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.00","spread":"25.860"},{"groupId":"OG001","value":"45.95","spread":"25.275"}]}]},{"title":"Visit 2 (Day 15) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"132"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"13.081"},{"groupId":"OG001","value":"-3.92","spread":"14.235"}]}]},{"title":"Visit 6 (Month 6) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.72","spread":"23.649"},{"groupId":"OG001","value":"48.14","spread":"25.484"}]}]},{"title":"Visit 6 (Month 6) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.95","spread":"13.247"},{"groupId":"OG001","value":"-2.40","spread":"14.457"}]}]},{"title":"Visit 8 (Month 12) Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.47","spread":"23.405"},{"groupId":"OG001","value":"49.67","spread":"24.501"}]}]},{"title":"Visit 8 (Month 12) Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.13","spread":"16.047"},{"groupId":"OG001","value":"-5.75","spread":"12.986"}]}]},{"title":"Final Visit - Actual Value","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.21","spread":"24.976"},{"groupId":"OG001","value":"49.00","spread":"25.078"}]}]},{"title":"Final Visit - Change from Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9.18","spread":"17.097"},{"groupId":"OG001","value":"-1.90","spread":"12.530"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the Stroke Impact Scale (SIS)","description":"The SIS consists of 59 items grouped in 8 domains: strength, hand function, activities of daily living (ADL) / instrumental activities of daily living (IADL), mobility, communication, emotion, memory and thinking, and participation/role function. The subject is asked to rate the level of difficulty in performing each item in the preceding week. Each item is scored on a 5-point scale ranging from 1 (inability to complete the item) to 5 (no difficulty experienced at all). For each domain, the SIS score will be calculated by summing all the items within the domain and transforming into a scale with a range of 0 to 100 as follows: SIS Score = 100 \\* \\[(Actual raw score - Lowest possible raw score)/ (Highest possible raw score-Lowest possible raw score)\\].","populationDescription":"The study was conducted in patients with chronic walking deficits from an ischemic stroke.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Day 1, up to 12 months","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"classes":[{"title":"SIS ADL/IADL - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"71.8","spread":"18.38"},{"groupId":"OG001","value":"75.1","spread":"16.56"}]}]},{"title":"SIS ADL/IADL Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":"18.57"},{"groupId":"OG001","value":"77.0","spread":"16.14"}]}]},{"title":"SIS ADL/IADL Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"9.13"},{"groupId":"OG001","value":"-0.2","spread":"8.99"}]}]},{"title":"SIS ADL/IADL Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"72.3","spread":"18.64"},{"groupId":"OG001","value":"73.8","spread":"15.14"}]}]},{"title":"SIS ADL/IADL Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"10.49"},{"groupId":"OG001","value":"-0.3","spread":"8.35"}]}]},{"title":"SIS Communication - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":"16.76"},{"groupId":"OG001","value":"88.3","spread":"17.81"}]}]},{"title":"SIS Communication Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":"16.43"},{"groupId":"OG001","value":"88.6","spread":"15.38"}]}]},{"title":"SIS Communication Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"9.85"},{"groupId":"OG001","value":"0.3","spread":"11.87"}]}]},{"title":"SIS Communication Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"83.6","spread":"22.74"},{"groupId":"OG001","value":"89.7","spread":"16.47"}]}]},{"title":"SIS Communication Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.33"},{"groupId":"OG001","value":"-2.5","spread":"8.97"}]}]},{"title":"SIS Emotion - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"67.3","spread":"13.08"},{"groupId":"OG001","value":"68.9","spread":"13.16"}]}]},{"title":"SIS Emotion Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"66.5","spread":"12.88"},{"groupId":"OG001","value":"65.7","spread":"12.08"}]}]},{"title":"SIS Emotion Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-1.01","spread":"15.56"},{"groupId":"OG001","value":"-2.7","spread":"14.26"}]}]},{"title":"SIS Emotion Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":"14.94"},{"groupId":"OG001","value":"67.0","spread":"14.37"}]}]},{"title":"SIS Emotion Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"12.77"},{"groupId":"OG001","value":"3.8","spread":"13.48"}]}]},{"title":"SIS Hand Function - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":"34.01"},{"groupId":"OG001","value":"48.4","spread":"34.79"}]}]},{"title":"SIS Hand Function Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":"34.81"},{"groupId":"OG001","value":"52.3","spread":"32.30"}]}]},{"title":"SIS Hand Function Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"17.57"},{"groupId":"OG001","value":"1.3","spread":"14.51"}]}]},{"title":"SIS Hand Function Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":"34.66"},{"groupId":"OG001","value":"54.0","spread":"31.95"}]}]},{"title":"SIS Hand Function Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"20.12"},{"groupId":"OG001","value":"3.3","spread":"16.40"}]}]},{"title":"SIS Memory & Thinking - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":"19.45"},{"groupId":"OG001","value":"82.8","spread":"19.91"}]}]},{"title":"SIS Memory & Thinking Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"84.0","spread":"19.32"},{"groupId":"OG001","value":"84.9","spread":"17.35"}]}]},{"title":"SIS Memory & Thinking Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"9.10"},{"groupId":"OG001","value":"0.9","spread":"10.86"}]}]},{"title":"SIS Memory & Thinking Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"80.7","spread":"20.51"},{"groupId":"OG001","value":"87.1","spread":"17.83"}]}]},{"title":"SIS Memory & Thinking Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"10.95"},{"groupId":"OG001","value":"-1.0","spread":"12.39"}]}]},{"title":"SIS Mobility - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":"18.98"},{"groupId":"OG001","value":"72.8","spread":"19.07"}]}]},{"title":"SIS Mobility Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":"18.52"},{"groupId":"OG001","value":"74.2","spread":"18.59"}]}]},{"title":"SIS Mobility Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"9.76"},{"groupId":"OG001","value":"-0.9","spread":"11.58"}]}]},{"title":"SIS Mobility Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":"16.66"},{"groupId":"OG001","value":"68.6","spread":"19.46"}]}]},{"title":"SIS Mobility Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"13.56"},{"groupId":"OG001","value":"-2.2","spread":"11.17"}]}]},{"title":"SIS Participation - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"64.8","spread":"26.08"},{"groupId":"OG001","value":"68.8","spread":"22.85"}]}]},{"title":"SIS Participation Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":"24.73"},{"groupId":"OG001","value":"70.7","spread":"21.95"}]}]},{"title":"SIS Participation Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"20.03"},{"groupId":"OG001","value":"1.4","spread":"15.97"}]}]},{"title":"SIS Participation Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":"23.95"},{"groupId":"OG001","value":"65.8","spread":"24.65"}]}]},{"title":"SIS Participation Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"18.86"},{"groupId":"OG001","value":"-3.1","spread":"19.26"}]}]},{"title":"SIS Physical Dimension Score (SIS 16) - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":"10.01"},{"groupId":"OG001","value":"64.5","spread":"9.94"}]}]},{"title":"SIS Physical Dimension Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":"10.14"},{"groupId":"OG001","value":"65.1","spread":"9.66"}]}]},{"title":"SIS Physical Dim. Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"5.13"},{"groupId":"OG001","value":"-0.6","spread":"5.31"}]}]},{"title":"SIS Physical Dimension Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":"9.52"},{"groupId":"OG001","value":"62.8","spread":"9.72"}]}]},{"title":"SIS Physical Dim. Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"6.73"},{"groupId":"OG001","value":"-1.3","spread":"4.92"}]}]},{"title":"SIS Strength - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"53.4","spread":"23.02"},{"groupId":"OG001","value":"53.3","spread":"22.34"}]}]},{"title":"SIS Strength Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":"24.46"},{"groupId":"OG001","value":"52.8","spread":"21.25"}]}]},{"title":"SIS Strength Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"15.85"},{"groupId":"OG001","value":"0.0","spread":"19.45"}]}]},{"title":"SIS Strength Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":"19.16"},{"groupId":"OG001","value":"51.8","spread":"21.54"}]}]},{"title":"SIS Strength Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"17.91"},{"groupId":"OG001","value":"-1.3","spread":"22.27"}]}]},{"title":"Stroke Recovery - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"60.3","spread":"21.42"},{"groupId":"OG001","value":"65.0","spread":"17.03"}]}]},{"title":"Stroke Recovery - Visit 6 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":"20.72"},{"groupId":"OG001","value":"66.4","spread":"17.19"}]}]},{"title":"Stroke Recovery Visit 6 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"15.08"},{"groupId":"OG001","value":"1.5","spread":"12.08"}]}]},{"title":"Stroke Recovery Visit 8 Actual","categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":"22.16"},{"groupId":"OG001","value":"67.4","spread":"18.03"}]}]},{"title":"Stroke Recovery Visit 8 Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"13.16"},{"groupId":"OG001","value":"1.8","spread":"13.32"}]}]}]},{"type":"SECONDARY","title":"Subject Global Impression (SGI)","description":"The Subject Global Impression (SGI) is single item measure of treatment response that asks the subject to rate the effects of the investigational drug on his or her overall walking ability using a 7 point scale ranging from 1 = \"Terrible\" to 7 = \"Delighted.\"","populationDescription":"The study was conducted in patients with chronic walking deficits from an ischemic stroke. These were the only participants to finish the SGI study due to study termination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Visit 8 (Month 12)","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"24"}]}],"classes":[{"title":"7 - Delighted","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"}]}]},{"title":"6 - Pleased","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}]},{"title":"5 - Somewhat Satisfied","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"}]}]},{"title":"4 - Neutral/Mixed","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"5"}]}]},{"title":"3 - Somewhat Dissatisfied","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"2 - Unhappy","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"1 - Terrible","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline on the 12-item Health Survey (SF-12)","description":"The SF-12 v2 (4-week recall) is a general health-related quality-of-life profile measure consisting of 12 items. The SF-12 Physical Component Summary (PCS) and the Mental Component Summary (MCS) scores will be derived and normed to a general United States population for score algorithm. The normalized PCS and MCS scores will be calculated at baseline, Month 12, and subsequent visits.\n\nSF-12 is a Physical and Mental Health Composite Scores (PCS \\& MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.","populationDescription":"The study was conducted in patients with chronic walking deficits from an ischemic stroke.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Day 1, up to 12 months","groups":[{"id":"OG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg"},{"id":"OG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"136"}]}],"classes":[{"title":"MCS - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"54.2","spread":"11.26"},{"groupId":"OG001","value":"54.4","spread":"10.00"}]}]},{"title":"MCS - Visit 8 - (Month 12) Actual","categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":"11.83"},{"groupId":"OG001","value":"54.5","spread":"11.60"}]}]},{"title":"MCS - Visit 8 - (Month 12) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"10.48"},{"groupId":"OG001","value":"-2.4","spread":"9.28"}]}]},{"title":"PCS - Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"36.2","spread":"9.11"},{"groupId":"OG001","value":"37.0","spread":"8.64"}]}]},{"title":"PCS - Visit 8 - (Month 12) Actual","categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":"8.12"},{"groupId":"OG001","value":"34.4","spread":"10.55"}]}]},{"title":"PCS - Visit 8 - (Month 12) Change from Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"7.42"},{"groupId":"OG001","value":"-2.3","spread":"7.50"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Date collected within 1 year.","description":"The Safety Population of 293 subjects included all subjects who received at least one dose of study treatment.\n\n\\*One subject was randomized but discontinued the study prior to receiving double-blind study treatment.","eventGroups":[{"id":"EG000","title":"Dalfampridine-ER 7.5 mg","description":"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 7.5 mg","deathsNumAffected":1,"deathsNumAtRisk":151,"seriousNumAffected":14,"seriousNumAtRisk":151,"otherNumAffected":102,"otherNumAtRisk":151},{"id":"EG001","title":"Dalfampridine-ER 10 mg","description":"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.\n\nSubjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study.\n\ndalfampridine-ER 10 mg","deathsNumAffected":0,"deathsNumAtRisk":142,"seriousNumAffected":8,"seriousNumAtRisk":142,"otherNumAffected":99,"otherNumAtRisk":142}],"seriousEvents":[{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Angina Unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Antrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Coronary Artery Disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Cellutiis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Escherichia Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Humerus Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Post Procedural Complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Basal Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Thyroid Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Complex Partial Seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Renal Failure Acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Peripheral Arterial Occlusive Disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Gastrointestinal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]}],"otherEvents":[{"term":"Ear And Labyrinth Disorders","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Eye Disorders","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":9,"numAtRisk":142}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":4,"numAtRisk":142}]},{"term":"Abdominal Discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Gastro esophageal Reflux Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Large Intestine Polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":142}]},{"term":"Gait Disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":11,"numAtRisk":142}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":151},{"groupId":"EG001","numAffected":5,"numAtRisk":142}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":151},{"groupId":"EG001","numAffected":19,"numAtRisk":142}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Ligament Sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Excoriation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Blood Creatinine Phosphokinase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":142}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":11,"numAtRisk":142}]},{"term":"Pain In Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":142}]},{"term":"Muscle Spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":5,"numAtRisk":142}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Musculoskeletal Stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Flank Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Joint Swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Basal Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":142}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":142}]},{"term":"Balance Disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":4,"numAtRisk":142}]},{"term":"Hypoesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":4,"numAtRisk":142}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Paresthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":7,"numAtRisk":142}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Hematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":3,"numAtRisk":142}]},{"term":"Renal Cyst","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":8,"numAtRisk":142}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Rhinorrhea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":151},{"groupId":"EG001","numAffected":5,"numAtRisk":142}]},{"term":"Hematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":2,"numAtRisk":142}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":151},{"groupId":"EG001","numAffected":6,"numAtRisk":142}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Coronary Artery Disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Sinus Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Angina Unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Diastolic Dysfunction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Dilatation Ventricular","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":151},{"groupId":"EG001","numAffected":0,"numAtRisk":142}]},{"term":"Myocardial Ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Pericardial Effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]},{"term":"Tricuspid Valve Incompetence","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":151},{"groupId":"EG001","numAffected":1,"numAtRisk":142}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding the study results for a period up to 30 days from the date the communication is submitted to the sponsor. The sponsor shall have the right to defer proposed publication an additional 60 days from the end of the review period. The sponsor cannot require changes to the communication and cannot unilaterally extend the embargo."},"pointOfContact":{"title":"Holy Roberts, Executive Medical Director - Medical Affairs","organization":"Acorda Therapeutics","email":"hroberts@acorda.com","phone":"914-326-5224"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000015761","term":"4-Aminopyridine"}],"ancestors":[{"id":"D000026902","term":"Potassium Channel Blockers"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M18011","name":"4-Aminopyridine","asFound":"Carotid Endarterectomy","relevance":"HIGH"},{"id":"M22861","name":"Potassium Channel Blockers","relevance":"LOW"}],"browseBranches":[{"abbrev":"ChanBlk","name":"Channel Blockers"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}